Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease
Top Cited Papers
Open Access
- 3 November 2010
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (17), 1903-1911
- https://doi.org/10.1001/jama.2010.1510
Abstract
Docosahexaenoic acid (DHA) is an omega-3 fatty acid identified as a potential treatment for Alzheimer disease. Epidemiological studies have shown that omega-3 fatty acid consumption reduces Alzheimer disease risk and DHA modifies the expression of Alzheimer-like brain pathology in mouse models.Keywords
This publication has 37 references indexed in Scilit:
- Benefits of fatty fish on dementia risk are stronger for those without APOE ε4Neurology, 2005
- A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse ModelJournal of Neuroscience, 2005
- Effect of n−3 fatty acid supplementation on lipid peroxidation and protein aggregation in rat erythrocyte membranesLipids, 1998
- Regional Membrane Phospholipid Alterations in Alzheimer's DiseaseNeurochemical Research, 1998
- Dietary fat intake and the risk of incident dementia in the Rotterdam studyAnnals of Neurology, 1997
- An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.1997
- Polyunsaturated Fatty Acids, Antioxidants, and Cognitive Function in Very Old MenAmerican Journal of Epidemiology, 1997
- The Neuropsychiatric InventoryNeurology, 1994
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Fatty acid composition of brain phospholipids in aging and in Alzheimer’s diseaseLipids, 1991